Pancreatic Cancer Research

ResearcherOslo University HospitalActive in the last 2 years

Caroline Sophie Verbeke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1111-9715; OpenAlex author ID A5018053923, A5023254706, A5124758096. Sources: OpenAlex.

Their work

Papers
72 (first author 10, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
134
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 5 papers · 2015: 4 papers · 2016: 4 papers · 2017: 4 papers · 2018: 3 papers · 2019: 6 papers · 2020: 3 papers · 2021: 6 papers · 2022: 2 papers · 2023: 6 papers · 2024: 8 papers · 2025: 9 papers · 2026: 9 papers

Papers 50 of 72

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Last author DOI 10.1002/gin2.70074↗
  2. Expression of glycolytic markers in cancer and stromal cells of treatment-naïve and neoadjuvantly treated pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00428-026-04478-2↗
  3. Reduced lipid metabolite abundance in human pancreatic cancer and matched serum samples following neoadjuvant FOLFIRINOX treatment. Last author DOI 10.1007/s11306-025-02388-z↗
  4. Proteomic characterization of primary pancreatic fibroblasts derived from neoadjuvant chemotherapy treated versus treatment-naïve PDAC. Co-author DOI 10.1016/j.jprot.2026.105660↗
  5. Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, … Co-author DOI 10.1016/s1470-2045(25)00567-4↗
  6. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  7. Comment on 'Horses out of the barn: pancreatic ductal adenocarcinoma frequently extends beyond the grossly visible tumour, requiring microscopic rectification … First author DOI 10.1111/his.70151↗
  8. Beyond Surgery: Does Adjuvant Therapy Still Add Value for Patients With Pancreatic Cancer After Neoadjuvant Treatment? First author DOI 10.1245/s10434-026-20630-3↗
  9. NFATC2 in pancreatic cancer-associated fibroblasts predicts treatment response and facilitates ERBB-targeted therapies Co-author DOI 10.64898/2026.04.04.716465↗
  10. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  11. Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreat… Last author DOI 10.1002/1878-0261.13759↗
  12. Spatial Transcriptomics Reveals Cancer and Stromal Cell Heterogeneity Between Center and Invasive Front of Pancreatic Cancer. Last author DOI 10.1016/j.modpat.2025.100726↗
  13. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  14. Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41597-025-04522-x↗
  15. Anatomical Classification and Staging Systems of Borderline Resectable and Locally Advanced Pancreatic Cancer-A Subgroup Analysis of the NORPACT-2 Trial. Co-author DOI 10.1245/s10434-025-17527-y↗
  16. Surgical, Histopathological, and Quality of Life Outcomes Following Neoadjuvant Chemotherapy and Pancreatectomy for Borderline Resectable and Locally Advanced … First author DOI 10.3390/cancers17152505↗
  17. Knowledge Discovery in Databases of Proteomics by Systems Modeling in Translational Research on Pancreatic Cancer. Co-author DOI 10.3390/proteomes13020020↗
  18. Proteomic Characterization of Primary Human Pancreatic Cancer Cell Lines Following Long-Term Exposure to Gemcitabine. Co-author DOI 10.3390/proteomes13040048↗
  19. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  20. Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1053/j.gastro.2024.05.028↗
  21. Performance and safety of diagnostic EUS FNA/FNB and therapeutic ERCP in patients with borderline resectable and locally advanced pancreatic cancer - results f… Co-author DOI 10.1080/00365521.2023.2290456↗
  22. Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer - real world data fro… Co-author DOI 10.1080/00365521.2024.2373115↗
  23. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis. Co-author DOI 10.1097/js9.0000000000000792↗
  24. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Last author DOI 10.1097/pas.0000000000002270↗
  25. Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific criteria. Last author DOI 10.1111/his.15190↗
  26. Automatic quantification of tumor-stroma ratio as a prognostic marker for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0301969↗
  27. Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1002/1878-0261.13344↗
  28. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  29. Artificial Intelligence in Pancreatic Ductal Adenocarcinoma Imaging: A Commentary on Potential Future Applications. Co-author DOI 10.1053/j.gastro.2023.04.003↗
  30. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective coho… Co-author DOI 10.1093/bjsopen/zrad137↗
  31. Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with LDHA- and MCT4-mediated enhanced glycolysis. Last author DOI 10.1186/s12935-023-02852-7↗
  32. Fatty acids abrogate the growth-suppressive effects induced by inhibition of cholesterol flux in pancreatic cancer cells. Co-author DOI 10.1186/s12935-023-03138-8↗
  33. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Last author DOI 10.1093/bjs/znac350↗
  34. Tumour Size and T-Stage in Pancreatic Cancer Resection Specimens Depend on the Pathology Examination Approach. Last author DOI 10.3390/cancers14102471↗
  35. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. First author DOI 10.1016/j.pan.2021.01.025↗
  36. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  37. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. Co-author DOI 10.1093/bjs/znaa031↗
  38. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  39. Pathology reporting of margin status in locally advanced pancreatic cancer: challenges and uncertainties. First author DOI 10.21037/jgo-20-391↗
  40. Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence. Last author DOI 10.3390/cancers13040895↗
  41. Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-65911-3↗
  42. Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing. Co-author DOI 10.3390/cancers12123628↗
  43. Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor. Co-author DOI 10.3390/cells9010227↗
  44. Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. Last author DOI 10.1016/j.hpb.2018.07.017↗
  45. Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2019.09.005↗
  46. Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-019-38603-w↗
  47. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. Co-author DOI 10.1186/s12885-019-5803-1↗
  48. Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer Cells. Last author DOI 10.3390/cells8010023↗
  49. Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic ca… Co-author DOI 10.3892/ijo.2018.4640↗
  50. Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. Co-author DOI 10.1016/j.pan.2018.04.010↗

Closest collaborators

The 25 strongest of 134 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Knut Jørgen Labori · 12 shared papers, 2017–2026 · strength 3.52
  2. Manoj Amrutkar · 14 shared papers, 2019–2026 · strength 2.98
  3. Ivar P. Gladhaug · 13 shared papers, 2016–2026 · strength 2.64
  4. Maia Blomhoff Holm · 5 shared papers, 2022–2026 · strength 1.84
  5. Ingvild Farnes · 5 shared papers, 2023–2025 · strength 1.24
  6. Matthias J. Löhr · 13 shared papers, 2015–2023 · strength 0.97
  7. Lars Aabakken · 3 shared papers, 2023–2024 · strength 0.71
  8. Dyre Berg Kleive · 3 shared papers, 2023–2025 · strength 0.70
  9. Pål‐Dag Line · 3 shared papers, 2023–2025 · strength 0.70
  10. Petra Sántha · 4 shared papers, 2019–2024 · strength 0.65
  11. Daniela M. Lenggenhager · 4 shared papers, 2018–2024 · strength 0.64
  12. Lodewijk A.A. Brosens · 4 shared papers, 2021–2024 · strength 0.57
  13. Oliver Strobel · 3 shared papers, 2019–2024 · strength 0.54
  14. Eline C. Soer · 3 shared papers, 2021 · strength 0.50
  15. Boris V. Janssen · 4 shared papers, 2021–2024 · strength 0.48
  16. Joanne Verheij · 4 shared papers, 2021–2024 · strength 0.48
  17. Marc G. Besselink · 4 shared papers, 2021–2024 · strength 0.48
  18. Iréne Esposito · 4 shared papers, 2018–2024 · strength 0.46
  19. Ulla Klaiber · 2 shared papers, 2024 · strength 0.45
  20. Carl-Stephan Leonhardt · 2 shared papers, 2024 · strength 0.45
  21. Carlos Fernández Moro · 5 shared papers, 2017–2020 · strength 0.43
  22. Sönke Detlefsen · 2 shared papers, 2021–2024 · strength 0.42
  23. Pierpaolo Vendittelli · 2 shared papers, 2023–2024 · strength 0.42
  24. Geert J. S. Litjens · 2 shared papers, 2023–2024 · strength 0.42
  25. Mathilde Resell · 2 shared papers, 2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.